Home / Health / Rethinking PSA: When Less is More
Rethinking PSA: When Less is More
31 Aug
Summary
- PSA tests can cause false positives, leading to unnecessary biopsies.
- Many slow-growing prostate cancers don't require immediate treatment.
- New methods focus on biomarkers and imaging over reflex biopsies.
Prostate cancer, a leading invasive cancer in men, is often slow-growing, leading to debate about routine PSA screening. While PSA tests can detect cancer early, their low specificity means many elevated results are false positives, triggering unnecessary biopsies. These biopsies and subsequent treatments, like surgery or radiation, can cause significant side effects such as incontinence and erectile dysfunction.
Further complicating the issue, a substantial percentage of "low-grade" prostate cancers may never progress to cause harm. Autopsy studies reveal many men have undiagnosed prostate cancer without symptoms during their lifetimes. In one study, prostate cancer mortality rates were similar across treated and actively monitored groups after 15 years.
Recent medical approaches shift from immediate biopsy for elevated PSA. Instead, providers may retest PSA, check for specific biomarkers, and use MRI to identify suspicious tumors. This refined strategy aims to reduce overdiagnosis and overtreatment, allowing for more selective interventions and prioritizing active surveillance when appropriate, making screening a personal choice based on individual risk tolerance.
